---
title: "In \"The Big Banks,\" Citigroup: WUXI BIO and WUXI XDC fell on Thursday due to non-fundamental drivers"
description: "Citi released a report stating that WUXI BIO and WUXI XDC fell approximately 7% and 8% respectively on Thursday, while Hong Kong CRO/CDMO companies overall dropped about 2% to 9%. Analysts believe tha"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277137974.md"
published_at: "2026-02-27T03:13:29.000Z"
---

# In "The Big Banks," Citigroup: WUXI BIO and WUXI XDC fell on Thursday due to non-fundamental drivers

> Citi released a report stating that WUXI BIO and WUXI XDC fell approximately 7% and 8% respectively on Thursday, while Hong Kong CRO/CDMO companies overall dropped about 2% to 9%. Analysts believe that this decline is not driven by fundamentals, but rather a result of position adjustments and capital flows. The current pullback is viewed as a technical short-term fluctuation, and the lack of catalysts in the market may lead to overselling of industry leaders, providing a more attractive entry point for investors holding for 3 to 12 months

Citi published a report indicating that WuXi Biologics (02269.HK) and WUXI XDC (02268.HK) fell approximately 7% and 8% on Thursday (26th), while the overall CRO/CDMO companies listed in Hong Kong dropped about 2% to 9%. The firm believes that this decline is not driven by fundamentals, but rather dominated by position adjustments and capital flows.

The report states that the current pullback is a technical/short-term fluctuation, rather than a result of deteriorating demand or execution capability. In the absence of catalysts during this market window, industry leaders may still experience overselling, which will create a more attractive entry opportunity for investors with a 3 to 12-month investment horizon

### Related Stocks

- [02269.HK - WUXI BIO](https://longbridge.com/en/quote/02269.HK.md)
- [159102.CN - Huaan Hang Seng Biotech ETF](https://longbridge.com/en/quote/159102.CN.md)
- [159615.CN - China Southern Hang Seng Biotech ETF(QDII)](https://longbridge.com/en/quote/159615.CN.md)
- [513700.CN - Penghua CSI HK Connect Health Care Composite ETF](https://longbridge.com/en/quote/513700.CN.md)
- [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md)
- [513120.CN - GF CSI HK Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/513120.CN.md)
- [159506.CN - Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF](https://longbridge.com/en/quote/159506.CN.md)
- [159892.CN - ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)](https://longbridge.com/en/quote/159892.CN.md)
- [02268.HK - WUXI XDC](https://longbridge.com/en/quote/02268.HK.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | [Link](https://longbridge.com/en/news/276822785.md) |
| Morgan Stanley's long position in Wuxi Biologics (Cayman) decreases to 2.11% on Jan 20 from 5.58%, HKEX shows | Morgan Stanley's long position in Wuxi Biologics (Cayman) decreases to 2.11% on Jan 20 from 5.58%, HKEX shows | [Link](https://longbridge.com/en/news/273496397.md) |
| Top Eminent Healthcare to Acquire Online Healthcare Platform in HK$100.3 Million Connected Deal | Top Eminent Healthcare Group Limited will acquire 100% of Top Eminent II Limited for HK$100.3 million, a connected trans | [Link](https://longbridge.com/en/news/277135842.md) |
| BeOne Medicines posts 2025 results and issues cautious 2026 outlook | BeOne Medicines Ltd, a biopharmaceutical company based in Switzerland and listed in Hong Kong, has released its unaudite | [Link](https://longbridge.com/en/news/277035413.md) |
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/en/news/276886600.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.